Patient and Tumour Characteristics Median age 60 years (26-92) Karnofsky Status:median 90 (50-100) Histology:SCC: n=120 (83%) Tumor size: ≥ 5 cm: n=78.

Slides:

Advertisements

Similar presentations

IMRT, Designed with Evidence-Based Bone Avoidance Objectives, Reduces the risk of Bone Fracture in the management of Extremity Soft Tissue Sarcoma Colleen.

Advertisements

CLINICAL WORKSHOP Image-Guided Adaptive Brachytherapy for Gynaecology Hospital name Participants’ names and roles Vienna, November 2013.

H. AlHussain, I. Busca, L. Eapen,, S. El-Sayed The Ottawa Hospital Cancer Center, University of Ottawa Department of Radiation Oncology.

University of Wisconsin

Anal Cancer Rob Glynne-Jones Mount Vernon Cancer Centre on behalf of NCRI anal cancer subgroup.

Morbidity / Complications

Impact of imaging on newer radiation techniques in Gynaecological cancer.

Stereotactic Body Radiation Therapy (SBRT): The optimal indication for operable tumors in inoperable patients D.Katsochi 1, S.Kosmidis 1, A.Fotopoulou.

NCI Workshop on Advanced Technologies in Radiation Oncology: Cervix December 1, 2006 David Gaffney MDPhD Huntsman Cancer Hospital University of Utah.

Prostate Radiotherapy A-Z

Hot topics in breast radiotherapy Mark Beresford.

Prof Ramesh S Bilimagga President AROI Group Medical Director - HCG.

Molecular Biomarkers in Radiotherapy of Cervical Cancer A collaboration project between Department of Gynecologic Oncology and Department of Radiation.

CET Cancer Center Oakland California High Dose Rate (HDR) Brachytherapy Gynecological Cancer D. Jeffrey Demanes M.D

Radiothérapie Hypofractionnée et Cancer de Prostate

Impact of overall treatment time and dose escalation on local control in locally advanced cervical cancer treated by chemo-radiation and image-guided adaptive.

Prevention by intravesical hyaluronic acid (Cystistat®) of acute radiation-induced cystitis in radiotherapeutic management of cervical cancer E. González.

Technological advances in Brachytherapy

Routine Use of Intraoperative Ultrasound Guidance during Intracavitary Brachytherapy Applicator Placement in Cervical Cancer: the University of Alabama.

Birga Terlunen-Traboldt ENT-Journal Club Need for Neck dissection after Radiochemotherapy? A study of the French GETTEC Group Vedrine P;Thariat J;Hitier.

Prof Stephen Langley Professor of Urology St Luke’s Cancer Centre, Guildford, UK PGMS, University of Surrey Focal Brachytherapy UK experience.

A Phase II Study to Evaluate the Safety and Toxicity of Sparing Radiation to the Pathologic N0 Side of the Neck in Squamous Cell.

Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,

Prostate Support Group Dr Duncan McLaren Consultant Oncologist.

Quantitative Dosimetric Analysis Of Patterns Of Local Relapse After IMRT For Primary Extremity Soft Tissue Sarcomas Ryan M. Lanning, Sean L. Berry, Michael.

Learn More At: CyberKnife Radiosurgery in the Treatment of Early and Advanced (Oligo-Metastases) Breast Cancer Sandra Vermeulen,

Radiation Therapy in the Management of Cervical Carcinoma Patrick S Swift, MD Medical Director, Radiation Oncology Alta Bates Comprehensive Cancer Center.

Image-Guided Adaptive Therapy for the Treatment of Lung Cancer

Comparison of SIB-IMRT and Conventional Accelerated Hyper-fractionated IMRT With Concurrent Cisplatin and Etoposide for Limited Disease SCLC Baosheng Li.

Mahatma Gandhi Cancer Hospital and Research Institute Dr P. S. Bhattacharyya, MD Radiation Oncologist. Elekta Synergy CT Simulator Flexitron HDR.

THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.

A prospective randomized trial

A Prospective Evaluation of FDG PET Adapted IMRT/VMAT for Node Positive GYN Cancers Junzo Chino MD, Irina Vergalasova PhD, Jeff Nawrocki BS, and Oana Craciunescu.

Adjuvant High-Dose-Rate Brachytherapy Alone for Stage I/II Endometrial Adenocarcinoma using a 4-Gray versus 6-Gray Fractionation Scheme Marie Lynn Racine,

Introduction/Aims There is less written about failure patterns after prostate brachytherapy (BT) alone or in combination with external beam radiotherapy.

Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,

Brachytherapy and GYN malignancy

FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,

Purpose and Objectives: To investigate

MOLECULAR RADIATION SCIENCES

IMPACT OF PHYSICAL DOSE RATE EFFECT ON THE LONG TERM RESULTS OF THE CF-252 BRACHYTHERAPY OF CERVIX CARCINOMA E. Janulionis; K.P.Valuckas; V.Atkocius; V.Samerdokiene.

Outcome of patients treated with Image Guided Brachytherapy for Locally Advanced Carcinoma of the Cervix at Royal Devon & Exeter Hospital Dr.

Taipei VGH Practice Guidelines: Oncology Guidelines Index Cancer of Oral Cavity Version Table of Content StagingStaging, Manuscript Taipei Veterans.

M ETHODS Median dose was 22Gy (range: ) in 1 to 5 fractions Median treatment volume was 12.6 cc (range: ). Assessed for eligibility.

To investigate the acute toxicity of 3D conformal concurrent chemo RT (Keeping PTV Dmax

SARC018: A SARC PILOT MULTICENTER STUDY OF PREOPERATIVE RADIATION AND SURGERY IN PATIENTS WITH HIGH- RISK DESMOID TUMORS Robert S. Benjamin, M.D.

PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,

PURPOSE PURPOSE METHODSMETHODS CONCLUSIONSCONCLUSIONS Long-term results of daily HDR brachytherapy in the postoperative setting of endometrial carcinoma.

Image Guided Interstitial Brachytherapy For Locally Advanced Gynaecological Cancer With A MUPIT Applicator M.A.D. Haverkort, MD 1, E. Van der Steen - Banasik,

Taipei VGH Practice Guidelines: Oncology Guidelines Index Cancer of Cervix Version Table of Content StagingStaging, Manuscript Taipei Veterans General.

방사선종양학과 - 혈액종양내과 Joint Conference 경희의료원 방사선종양학과 R4 공 문 규.

Taipei Veterans General Hospital Practices Guidelines Oncology Cervical Cancer Version VGH Survival Data as of YYYY/MM/DD Proofing on 2010/MM/DD.

Taipei Veterans General Hospital Practices Guidelines Oncology Rectal Cancer Version

Bladder Cancer R. Zenhäusern.

T Sammour, BA Price, KJ Krause, GJ Chang

THREE OR FOUR FRACTIONS PER WEEK IN POSTOPERATIVE HIGH DOSE RATE BRACHYTHERAPY (HDRBT) FOR ENDOMETRIAL CARCINOMA (EC). Rovirosa A1, Vargas M1, Ascaso C2,

Results of Definitive Radiotherapy in Anal Canal Carcinoma

Rationale in the Single Session Treatment of Lung Tumors

Cervical Cancer Tiffany Smith HCP 102.

นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี

Prof. Shaila Anwar Professor Obs & Gynae

Institute of Oncology “Ion Chiricuță”, Cluj, Romania

Figure 1. The (a) anterior–posterior and (b) right-lateral fields and (c, d) the isodose distributions of two axial planes in one patient with T2 stage.

RTOG 0126 A Phase III Randomized Study of High Dose 3D-CRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer Bijoy.

The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies Richard Pötter,

ACT II: The Second UK Phase III Anal Cancer Trial

Figure 3 Target volume definitions

Peter de Boer, Stefano Mandija, Anita M

Presentation transcript:

Patient and Tumour Characteristics Median age 60 years (26-92) Karnofsky Status:median 90 (50-100) Histology:SCC: n=120 (83%) Tumor size: ≥ 5 cm: n=78 (52%) ≤Ib1,IIA=18(12%) Lymph node involvement: n=57 (39%) - EBT: 45 Gy/1,8 Gy per fraction - HDR–BT: 4 x 7 Gy (40 Gy (EQD2)) pt A/HR CTV - Since 2001 (D90): total dose 85+ Gy (EQD2) - Intracavitary + interstitial, if insufficient response - Cis-Platinum 5x40mg/m2 (57%), since 4/99 Treatment schedule (Overall treatment time 6-7 weeks)

HR CTV concept GTV, HR CTV+OAR contouring Biological modelling (linear-quadratic) Dose Volume constraints: OAR (2 cm 3 ): 75/90 Gy (EQD2, α/ β3) Prescription: HR CTV - (D90): Gy(EQD2, α/ β10) Prospective 3D image based optimisation MRI based Treatment Planning Major Learning Period: (n=73) Systematic prospective protocol since 2001 (n=72) no systematic prospective protocol (point A/OAR)

Outcome after complete remission non central true pelvic and distant recurrence non central true pelvic central true pelvic recurrence pelvic lymph node and distant pelvic lymph node distant recurrence disease free (64%) n=138 Treatment time: Median follow up: 39 months

Stage IIB, Large Tumour, ≥ 5 cm (treated 12/2002) Before EBRT: 5 cm wide, 5 cm thick, 7 cm high: 85 cm 3 At 1. Brachytherapy after EBRT:2 cm x 3 cm x 3 cm, 9 cm 3, 6 months after treatment: Radioth&Oncol 2005 Continuous Complete Remission good remission, sufficient for intracavitary BT Initial tumor extension

Stage IIIB- (treated 11/1998) Insufficient response-no adaptation of application technique At Brachytherapy after EBRT 9 months after treatment Dose distribution at brachytherapy At time of diagnosis Residual tumorInsufficient adaptationRecurrence Initial tumor extension

Tumor size < 5cm ≥5cm CCR at 3 years: Vienna (335 patients) 100% 91% Total:Events: < 5cm n=34n=0 ≥5 cm n=38n=4 (28) (12) (4) (30) (17) (9) 96% 72% Total:Events: < 5cm n=33n=1 (at 36m) ≥5 cm n=40n=10 (30) (26) (22) (23) (15) (10) CCR true pelvis (98-00) CCR true pelvis (01-03)

Late side effects at 3 years LENT/SOMA: absolute numbers G 0G 1G 2G 3G 4 Bladder Rectum Intestines Total PeriodPts.G

Conclusion MRI assisted treatment planning in intracavitary cervical cancer brachytherapy plus risk adapted interstitial brachytherapy + cis-Platinum (145 consecutive patients) High local control tumors < 5 cm: up to 100% tumors ≥ 5 cm: ~ 90% Low rate of side effects G3/4: < 5% (crude)